However, prior research data strongly suggest that the blocking of CD47-SIRPα interaction with tumor opsonizing antibodies (such as anti-CD20 rituximab, or, anti-EGFR cetuximab, or anti-Her2 trastuzumab) can significantly lead to cancer cell clearance especially in case of liver cancer through suppressing cancer cell-expressed CD47 proteins [86, 88–90]. Here, CD47 is linked to liver cancer.